Accessibility Menu

Laboratorios Farmaceuticos Rovi(FRA) 41L

Market Cap€3.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€60.65
-1.30%
-0.80Today

Laboratorios Farmaceuticos Rovi Financials at a Glance

Market Cap

€3.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€773.05

Net Income (TTM)

€185.04

EPS (TTM)

€3.62

P/E Ratio

16.79

Dividend

€0.96

Beta (Volatility)

0.05 (Low)

Price

€60.65

Volume

0

Open

€60.65

Previous Close

€60.65

Daily Range

€60.65 - €60.65

52-Week Range

€53.10 - €85.65

Estimated Earnings Date

N/A

41L News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,232

CEO

Juan López-Belmonte Encina

Website

www.rovi.es

41L Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

29.30%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

5.96%

Dividend Yield

1.58%

Payout Ratio

N/A

Stock Overview

Market Cap

€3.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.14M

Volume

0

Avg. Volume

7.288

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Laboratorios Farmaceuticos Rovi Performance Analysis

Laboratorios Farmaceuticos Rovi annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 817,698,00026.1%
20232023-12-31EUR 829,509,0001.4%
20242024-12-31EUR 763,749,000-7.9%
20252025-12-31EUR 743,483,000-2.7%
Laboratorios Farmaceuticos Rovi annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 3.7335.2%
20232023-12-31EUR 3.29-12.0%
20242024-12-31EUR 2.68-18.6%
20252025-12-31EUR 2.752.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€191.67

+1.2%

Gross Profit

€121.82

+1.2%

Gross Margin

63.56%

+1.0%

Market Cap

€3.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€1.35

N/A

Employees

2,232

N/A

Net Income

€74.93

+3.5%

EBITDA

€27.85

+0.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€234.66

+33.8%

Total Debt

€107.69

+0.8%

Accounts Receivable

€162.43

+1.2%

Inventory

€272.81

+0.8%

Long Term Debt

€80.54

+0.8%

Short Term Debt

€27.15

+1.0%

Return on Assets

18.55%

+1.2%

Return on Invested Capital

26.18%

+1.0%

Free Cash Flow

€59.95

-17.6%

Operating Cash Flow

€81.33

+9.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 41L

What is the current price of Laboratorios Farmaceuticos Rovi?

Laboratorios Farmaceuticos Rovi is trading at €60.65 per share.

What is the 52-week range for Laboratorios Farmaceuticos Rovi?

Over the past 52 weeks, Laboratorios Farmaceuticos Rovi has traded between €53.10 and €85.65.

How much debt does Laboratorios Farmaceuticos Rovi have?

As of the most recent reporting period, Laboratorios Farmaceuticos Rovi reported total debt of €107.69M.

How much cash does Laboratorios Farmaceuticos Rovi have on hand?

Laboratorios Farmaceuticos Rovi reported €126.97M in cash and cash equivalents in its most recent financial results.

What is Laboratorios Farmaceuticos Rovi’s dividend yield?

Laboratorios Farmaceuticos Rovi currently has a dividend yield of 1.58%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services